Drug Type Small molecule drug |
Synonyms BPI 361175, BPI361175 |
Action inhibitors |
Mechanism EGFR C797S inhibitors(Epidermal Growth Factor Receptor C797S inhibitors), EGFR T790M inhibitors(Epidermal Growth Factor Receptor T790M inhibitors), EGFR exon 19 deletion inhibitors |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Lung Non-Small Cell Carcinoma | Phase 2 | - | 01 Jul 2023 | |
Advanced Malignant Solid Neoplasm | Phase 2 | China | 21 Jul 2021 | |
Recurrent Non-Small Cell Lung Cancer | Phase 2 | China | 21 Jul 2021 | |
EGFR-mutated non-small Cell Lung Cancer | Phase 1 | China | 21 Jul 2021 |